4D Molecular Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $15 | $14 | $1 | $3 |
Gross Profit | -1,873 | 14 | -1,783 | 3 |
EBITDA | -59,456 | -51,867 | -61,038 | -49,429 |
EBIT | -61,344 | -53,621 | -56,117 | -51,132 |
Net Income | -54,658 | -47,972 | -49,671 | -43,843 |
Net Change In Cash | 15 | 14 | 1 | 3 |
Free Cash Flow | -43,377 | -47,758 | -46,812 | -28,332 |
Cash | 77,159 | 133,526 | 149,336 | 187,539 |
Basic Shares | 55,927 | 55,744 | 53,943 | 55,554 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $37 | $20,723 | $3,129 | $18,038 |
Gross Profit | 37 | -76,373 | 3,129 | 18,038 |
EBITDA | -187,841 | -107,118 | -106,152 | -68,313 |
EBIT | -194,546 | -112,867 | -110,032 | -71,333 |
Net Income | -160,868 | -100,837 | -101,076 | -68,297 |
Net Change In Cash | 37 | 20,723 | 3,129 | 18,038 |
Cost of Revenue | -100,650 | -123,725 | ||
Free Cash Flow | -138,371 | -78,563 | -98,221 | -78,244 |
Cash | 149,336 | 249,108 | 218,642 | 315,429 |
Basic Shares | 53,943 | 39,130 | 32,351 | 27,730 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.98 |
2025-03-31 | -$0.86 |
2024-12-31 | -$0.90 |
